01/31/23 7:00 AMNasdaq : DCPH earningsDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023. In connection with the earnings release, Deciphera’...RHEA-AIneutral
01/24/23 4:02 PMNasdaq : DCPH offeringDeciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters'; Option to Purchase Additional SharesDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common stock. The securities described above were offered by Deciphera...RHEA-AIneutral
01/24/23 4:01 PMNasdaq : DCPH clinical trialDeciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK ® using circulating...RHEA-AIpositive
01/19/23 7:56 PMNasdaq : DCPH offeringDeciphera Pharmaceuticals Announces Pricing of Public Offering of Common StockDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share.RHEA-AIneutral
01/18/23 4:54 PMNasdaq : DCPH offeringDeciphera Pharmaceuticals Announces Proposed Public Offering of Common StockDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering. A preliminary prospectus supplement and...RHEA-AIneutral
01/03/23 4:02 PMNasdaq : DCPH Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product CompanyDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2023 and planned 2023 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2022 revenue.RHEA-AIvery positive
01/03/23 4:01 PMNasdaq : DCPH clinical trialDeciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 OnlyDeciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA from a subgroup of...RHEA-AIneutral
01/03/23 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDeciphera Pharmaceuticals, Inc. today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.RHEA-AIneutral
12/01/22 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology SummitDeciphera Pharmaceuticals, Inc. today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 10:40 AM ET. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United...RHEA-AIneutral
11/08/22 7:00 AMNasdaq : DCPH conferencesDeciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor ConferencesDeciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences:. Stifel Healthcare Conference on Tuesday, November 15, 2022 at 10:55 AM ET in New York, NY Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 8:30 AM ET/ 1:30 PM GMT in London,...RHEA-AIneutral